Add time:08/29/2019         Source:sciencedirect.com

Background & AimsPrevious studies have indicated that serotonin-3–receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women.

We also recommend Trading Suppliers and Manufacturers of Ramosetron hydrochloride (cas 132907-72-3). Pls Click Website Link as below: cas 132907-72-3 suppliers